An interventional study of Motivational Interviewing-Cognitive Behavioral Therapy and Brief Education in Relapsing-remitting Multiple Sclerosis, sponsored by University of Missouri, Kansas City. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-02.
Sponsored by University of Missouri, Kansas City · Not applicable, Interventional, and Health services research
As many as 50% of MS patients prematurely discontinue their disease modifying medications. For this study, we will develop a telephone-based talk therapy intervention and then conduct a randomized controlled trial. Patients will be assigned to either 5 weekly 20 minute telephone sessions of psychotherapy or a brief education control condition. We hypothesize that patients undergoing phone therapy will be more likely to indicate they are interested in resuming taking disease modifying medications than patients given brief education and treatment as usual.
3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.
This study's enrollment of 80 is above the median of 50 across 2,342 interventional studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →University of Missouri, Kansas City is the lead sponsor of 47 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients receive a brief educational packet along with treatment as usual
Behavioral: Brief Education
Patients receive five 20 minute phone sessions of motivational interviewing/cognitive behavioral therapy weekly along with a brief educational packet.
Behavioral: Motivational Interviewing-Cognitive Behavioral Therapy · Behavioral: Brief Education
A telephone based talk therapy discussing pros and cons of medication use in MS.
Give patients a pamphlet discussing pros and cons of disease modifying therapies
Adherence Treatment Survey
Whether the patient indicates if he/she decided to re-initiate disease modifying therapies on a "yes"/"no" question.
Time frame: 10 weeks after enrollment
Adherence Treatment Survey
Whether the patient reports that he/she plans to discuss disease modifying therapies with a care provider on a "yes"/"no" question.
Time frame: 10 weeks after enrollment
Adherence Treatment Survey
Whether the patient reports that he/she plans to discuss disease modifying therapies with a care provider on a "yes"/"no" question.
Time frame: 5 weeks after enrollment
Adherence Treatment Survey
Whether the patient indicates if he/she decided to re-initiate disease modifying therapies on a "yes"/"no" question.
Time frame: 5 weeks after enrollment
Motivation/Readiness Questionnaire
Whether there is increased self-reported motivation to take disease modifying therapies on a 1-10 likert-type scale.
Time frame: 10 weeks post-enrollment
Motivation/Readiness Questionnaire
Whether there is an increase in self-reported motivation to take disease modifying therapies on a 1-10 likert-type scale.
Time frame: 5 weeks post-enrollment
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Missouri, Kansas City